← The SEC Ephemeris: the whole map
Immunomedics, Inc sacituzumab govitecan
In the graph: all 1 documents (4 pages).
- Application
- BLA 761115
- Ticker
- Immunomedics, Inc
- Product
- sacituzumab govitecan
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- January 17, 2019
From FDA letters and SEC filings. Not investment or medical advice.